No­var­tis’ CAR-T part­ner in Chi­na wraps $383M take-pri­vate deal en­gi­neered by CEO

Af­ter 13 years on Nas­daq, Cel­lu­lar Bio­med­i­cine Group is re­turn­ing to pri­vate hands.

CEO Tony (Bizuo) Liu is a key ad­vo­cate of the deal, lead­ing a con­sor­tium of most­ly Chi­nese in­vestors in­clud­ing oth­er top com­pa­ny ex­ecs, Yun­feng Cap­i­tal and TF Cap­i­tal — even as the com­pa­ny is get­ting more en­trenched in the US with its CAR-T and oth­er cell ther­a­py work.

Share­hold­ers are re­ceiv­ing $19.75 per share $CB­MG, which trans­lates to a pre­mi­um of 31.4% over the 30 trad­ing-day av­er­age price as of Au­gust 11. The stock, though, has dropped sig­nif­i­cant­ly since the con­sor­tium first put in its pro­pos­al in No­vem­ber. Com­pared to then, the ac­qui­si­tion price marks on­ly a 11.8% in­crease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.